Stock Market Impact: Demant A/S shares rose approximately 3% after Bank of America (BofA) Securities upgraded the rating to “buy” from “underperform” and increased the price objective to DKK280, representing a 64.7% uplift from the prior target of DKK170.
Analyst Rationale: The upgrade was driven by three main factors: (1) a hearing‑aid market that grew about 5% in Q1 2026, exceeding the 2‑4% full‑year guidance from most manufacturers; (2) early market traction for Demant’s new Oticon Zeal product; (3) an improved earnings‑risk profile suggesting potential upgrades rather than downgrades.
Market Context: The four largest hearing‑aid manufacturers (Demant, GN, Sonova, WS Audiology) together hold >90% of global market share. Their Q1 unit growth rates were Demant 9%, GN 9%, Sonova 11%, WS ‑6%. BofA estimates overall market growth at 5.4% for the quarter and 4.6% on a three‑year rolling basis.
Growth Assumptions: BofA considers a 4% full‑year market growth assumption conservative; a 4% outcome would imply an 18% revenue contraction for private competitor Starkey, deemed unlikely.
Product Outlook – Oticon Zeal: Consensus forecasts suggest Zeal sales of ~70,000 units in 2026, less than 2% of its serviceable addressable market of 3.81 million units. BofA projects Zeal could generate DKK76 million revenue from the U.S. Veterans Affairs channel in 2026, assuming a 2% volume share and $600 average selling price.
Financial Forecasts: BofA now expects 7.5% organic growth for Demant’s Hearing Aids segment in 2026 (vs. consensus 7.2%). EPS estimates are raised to DKK13.13 for 2026 (+8.1%) and DKK14.87 for 2027 (+9.5%). Revenue estimate for 2026 is lifted to DKK25.93 billion (from DKK25.29 billion). The weighted average cost of capital (WACC) is lowered to 7.9% from 8.7%.
Valuation Methodology: The DKK280 price target derives from three valuation approaches: EV/EBITDA multiple of 13.5× (implies DKK303/share), discounted cash flow using 7.9% WACC (implies DKK276), and P/E multiple of 18.5× (implies DKK259).
Competitive Risks: Costco is identified as a competitive risk; BofA estimates Demant could lose about DKK140 million in Hearing Aids revenue in 2027 if Sonova captures a 20% share of Costco’s business and one‑third of those gains come at Demant’s expense, equating to roughly a 0.5% drag on group revenue.
Balance‑Sheet Highlights: As of December 2025, Demant’s market capitalization stood at DKK53.45 billion with 211.8 million shares outstanding; net debt was DKK19.66 billion.
